# iRhythm Technologies, Inc.

Summary updated: 2026-10-02T13:52:49.219603Z
Canonical: https://finbar.com/research/companies/irhythm-technologies-inc

## Overview

iRhythm Technologies, Inc. is a digital health and medical technology company focused on cardiac rhythm monitoring. Its core Zio service combines a prescription ECG patch with software-based analysis and a report for the prescribing physician; the Zio monitor records ECG continuously for up to 14 days. [1](https://app.finbar.com/go?id=P62613382) The company’s stated mission is to create trusted solutions to detect and prevent disease. [2](https://www.irhythmtech.com/us/en/who-we-are/trust-center)

Founded in 2006 and headquartered in San Francisco, iRhythm reported $747.1 million in revenue for 2025 and approximately 2,400 regular full-time employees at year-end. [3](https://app.finbar.com/go?id=P23214428)[4](https://app.finbar.com/go?id=P64115874) Its business is primarily centered on the U.S., with Zio service launched in Japan in 2025; the company also reported facilities in the United States, Manila, and London. [5](https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx)[6](https://app.finbar.com/go?id=T275050)
[1](https://app.finbar.com/go?id=P62613382)[2](https://www.irhythmtech.com/us/en/who-we-are/trust-center)[3](https://app.finbar.com/go?id=P23214428)[4](https://app.finbar.com/go?id=P64115874)[5](https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx)[6](https://app.finbar.com/go?id=T275050)[2](https://www.irhythmtech.com/us/en/who-we-are/trust-center)[5](https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx)

## Products & services

iRhythm’s Zio monitor is a prescription-only wearable ECG patch that records heart activity continuously for up to 14 days. After the wear period, its ZEUS software analyzes the recorded ECG for specified arrhythmias, and a report is provided electronically to the prescribing physician. The current Zio monitor is described as 72% smaller, 62% lighter, and 23% thinner than the prior-generation Zio XT; it also has breathable adhesive, Bluetooth connectivity, and improved processing efficiency. Zio XT is the previous-generation patch monitor, also designed for continuous recording for up to 14 days. [1](https://app.finbar.com/go?id=P62613382)[7](https://app.finbar.com/go?id=P106531874)[8](https://app.finbar.com/go?id=P33245069)

Zio AT combines a prescription ECG patch, which records continuously for up to 14 days, with a wireless gateway that connects the patch to ZEUS during wear and transmits data to the cloud over LTE. iRhythm’s monitoring services include long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry. For long-term monitoring, the patch can capture about 1.5 million heartbeats over up to 14 consecutive days; ZEUS-detected events and technician analysis contribute to a comprehensive end-of-wear report. [9](https://app.finbar.com/go?id=P37981510)[10](https://app.finbar.com/go?id=P150395244)[11](https://app.finbar.com/go?id=P66747415) A 2025 investor presentation described proposed Zio MCT features including up to 21-day wear and enhanced detection and reporting, but stated that the product was not yet FDA-cleared at that time. [12](https://app.finbar.com/go?id=T19731626)[13](https://app.finbar.com/go?id=P196069388) The cited filing reports revenue growth for Zio monitor and Zio AT together but does not give individual product revenue shares. [14](https://app.finbar.com/go?id=P150395557)
[1](https://app.finbar.com/go?id=P62613382)[7](https://app.finbar.com/go?id=P106531874)[8](https://app.finbar.com/go?id=P33245069)[9](https://app.finbar.com/go?id=P37981510)[10](https://app.finbar.com/go?id=P150395244)[11](https://app.finbar.com/go?id=P66747415)[12](https://app.finbar.com/go?id=T19731626)[13](https://app.finbar.com/go?id=P196069388)[14](https://app.finbar.com/go?id=P150395557)

## Geographic presence

iRhythm Technologies’ operations are centered in the United States, with its headquarters and clinical center in San Francisco and a manufacturing facility in Cypress, California. It also lists clinical centers in Deerfield, Illinois; Houston, Texas; and Manila, Philippines, and corporate office space in Solana Beach, California, and London, UK. [15](https://app.finbar.com/go?id=P87239981)

Outside the US, the company describes commercial activity in the UK, selected European countries, and Japan. Its small direct European sales team covers Switzerland, Austria, and the Netherlands; distribution arrangements support Spain and other European markets. In the UK, it has a small direct sales and clinical infrastructure in Bagshot, Surrey. Japan sales and fulfillment use a third-party distributor, and the company launched its service there in May 2025. [16](https://app.finbar.com/go?id=P56762977) [17](https://app.finbar.com/go?id=P15186887) [5](https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx) FY2025 reporting does not provide revenue by country or region; it describes the business as one reporting unit. [18](https://app.finbar.com/go?id=P16411851)
[15](https://app.finbar.com/go?id=P87239981)[16](https://app.finbar.com/go?id=P56762977)[17](https://app.finbar.com/go?id=P15186887)[5](https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx)[18](https://app.finbar.com/go?id=P16411851)[5](https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx)

## Business segments

iRhythm Technologies reports one operating and reportable segment: its global ambulatory cardiac monitoring business. The company’s offerings within this segment include long-term continuous cardiac monitoring and mobile cardiac telemetry services used to detect and diagnose arrhythmias. These offerings are not reported as separate segments. [19](https://app.finbar.com/go?id=P81624133)[11](https://app.finbar.com/go?id=P66747415)

The single reportable segment represents 100% of reported company revenue; the company does not disclose revenue contributions for separate product or service segments. Its 2026 second-quarter filing confirms the one-segment structure. [20](https://app.finbar.com/go?id=P150395289)
[19](https://app.finbar.com/go?id=P81624133)[11](https://app.finbar.com/go?id=P66747415)[20](https://app.finbar.com/go?id=P150395289)

## Company history

iRhythm Technologies was founded in 2006 by Dr. Uday N. Kumar, who developed the company out of Stanford Biodesign’s Innovation Fellowship. [21](https://med.stanford.edu/biodesign/our-impact/technologies/irhythm.html) Its Zio Patch received FDA clearance in 2009 and entered U.S. commercial launch in 2011; in 2010, iRhythm also announced a co-marketing partnership with St. Jude Medical. [22](https://www.fiercebiotech.com/medical-devices/irhythm-has-ce-mark-sight-for-arrhythmia-dx-patch) [23](https://www.prnewswire.com/news-releases/st-jude-medical-and-irhythm-technologies-enter-into-partnership-to-co-market-novel-cardiac-rhythm-monitor-93632259.html)

The company went public in October 2016, and the FDA cleared its Zio AT ECG Monitoring System in 2017. [24](https://investors.irhythmtech.com/news/news-details/2016/iRhythm-Technologies-Announces-Pricing-of-Initial-Public-Offering/default.aspx) [25](https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163512.pdf) After a series of CEO transitions in 2020–21, Quentin Blackford became president and CEO in October 2021. [26](https://investors.irhythmtech.com/news/news-details/2020/iRhythm-Technologies-President-and-CEO-Kevin-King-to-Retire-Michael-Coyle-Joins-Company-as-President-and-CEO-Effective-January-12-2021/default.aspx) [27](https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Announces-Leadership-Transition/default.aspx) [28](https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Names-Quentin-Blackford-President-and-Chief-Executive-Officer/default.aspx) In 2023, iRhythm launched a next-generation Zio monitor and enhanced service. [29](https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx) In 2026, it completed a holding-company reorganization, with iRhythm Holdings becoming successor registrant, and announced a proposed acquisition of VitalConnect. [30](https://app.finbar.com/go?id=P34085353) [31](https://investors.irhythmtech.com/news/news-details/2026/iRhythm-to-Acquire-VitalConnect-Expanding-Its-Cardiac-Monitoring-Platform-Across-Ambulatory-Inpatient-and-Hospital-to-Home-Care/default.aspx)
[30](https://app.finbar.com/go?id=P34085353)[21](https://med.stanford.edu/biodesign/our-impact/technologies/irhythm.html)[22](https://www.fiercebiotech.com/medical-devices/irhythm-has-ce-mark-sight-for-arrhythmia-dx-patch)[23](https://www.prnewswire.com/news-releases/st-jude-medical-and-irhythm-technologies-enter-into-partnership-to-co-market-novel-cardiac-rhythm-monitor-93632259.html)[24](https://investors.irhythmtech.com/news/news-details/2016/iRhythm-Technologies-Announces-Pricing-of-Initial-Public-Offering/default.aspx)[25](https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163512.pdf)[26](https://investors.irhythmtech.com/news/news-details/2020/iRhythm-Technologies-President-and-CEO-Kevin-King-to-Retire-Michael-Coyle-Joins-Company-as-President-and-CEO-Effective-January-12-2021/default.aspx)[27](https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Announces-Leadership-Transition/default.aspx)[28](https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Names-Quentin-Blackford-President-and-Chief-Executive-Officer/default.aspx)[29](https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx)[31](https://investors.irhythmtech.com/news/news-details/2026/iRhythm-to-Acquire-VitalConnect-Expanding-Its-Cardiac-Monitoring-Platform-Across-Ambulatory-Inpatient-and-Hospital-to-Home-Care/default.aspx)

## Sources

1. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P62613382)
2. [www.irhythmtech.com](https://www.irhythmtech.com/us/en/who-we-are/trust-center)
3. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P23214428)
4. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P64115874)
5. [investors.irhythmtech.com](https://investors.irhythmtech.com/news/news-details/2025/iRhythm-Launches-Zio-Long-Term-Continuous-Monitoring-Service-in-Japan-as-the-Zio-ECG-Recording-and-Analysis-System-Advancing-AI-Powered-Arrhythmia-Detection/default.aspx)
6. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T275050)
7. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P106531874)
8. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P33245069)
9. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P37981510)
10. [iRhythm Technologies, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150395244)
11. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P66747415)
12. [iRhythm Technologies, Inc. — Presentation (2025 Y), p7](https://app.finbar.com/go?id=T19731626)
13. [iRhythm Technologies, Inc. — Presentation (2025 Y), p9](https://app.finbar.com/go?id=P196069388)
14. [iRhythm Technologies, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150395557)
15. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P87239981)
16. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P56762977)
17. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P15186887)
18. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P16411851)
19. [iRhythm Technologies, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P81624133)
20. [iRhythm Technologies, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150395289)
21. [med.stanford.edu](https://med.stanford.edu/biodesign/our-impact/technologies/irhythm.html)
22. [www.fiercebiotech.com](https://www.fiercebiotech.com/medical-devices/irhythm-has-ce-mark-sight-for-arrhythmia-dx-patch)
23. [www.prnewswire.com](https://www.prnewswire.com/news-releases/st-jude-medical-and-irhythm-technologies-enter-into-partnership-to-co-market-novel-cardiac-rhythm-monitor-93632259.html)
24. [investors.irhythmtech.com](https://investors.irhythmtech.com/news/news-details/2016/iRhythm-Technologies-Announces-Pricing-of-Initial-Public-Offering/default.aspx)
25. [www.accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163512.pdf)
26. [investors.irhythmtech.com](https://investors.irhythmtech.com/news/news-details/2020/iRhythm-Technologies-President-and-CEO-Kevin-King-to-Retire-Michael-Coyle-Joins-Company-as-President-and-CEO-Effective-January-12-2021/default.aspx)
27. [investors.irhythmtech.com](https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Announces-Leadership-Transition/default.aspx)
28. [investors.irhythmtech.com](https://investors.irhythmtech.com/news/news-details/2021/iRhythm-Technologies-Names-Quentin-Blackford-President-and-Chief-Executive-Officer/default.aspx)
29. [investors.irhythmtech.com](https://investors.irhythmtech.com/news/news-details/2023/iRhythm-Launches-Next-Generation-Zio-Monitor-and-Enhanced-Zio-Service-Its-Smallest-Lightest-and-Thinnest-Cardiac-Monitor/default.aspx)
30. [iRhythm Technologies, Inc. — Press release (2025 Y)](https://app.finbar.com/go?id=P34085353)
31. [investors.irhythmtech.com](https://investors.irhythmtech.com/news/news-details/2026/iRhythm-to-Acquire-VitalConnect-Expanding-Its-Cardiac-Monitoring-Platform-Across-Ambulatory-Inpatient-and-Hospital-to-Home-Care/default.aspx)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.